Skip to main content
Veracyte Inc (VCYT)
Drugs • Health Care
Stock AI
News & Reports
July 09, 2026 Veracyte Inc. Set to Announce Q2 2026 Financial Results Veracyte, Inc. is set to announce its Q2 2026 financial results on July 30, followed by a conference call to discuss its business developments. The company continues to lead in cancer diagnostics with innovative tests aimed at improving patient care.
June 01, 2026 Veracyte Inc. Launches Prosigna Breast Test: A New Era in Personalized Cancer Care Veracyte's Prosigna Breast Risk of Recurrence test offers personalized insights for early-stage hormone-receptor positive breast cancer patients. Launching on June 8, 2026, it integrates biological and clinical data to enhance treatment decisions and improve patient care.
May 30, 2026 Veracyte Inc. Reports Groundbreaking Findings from ENZAMET Trial on Decipher Prostate Test Veracyte has announced groundbreaking results from the ENZAMET trial, revealing that its Decipher Prostate test can effectively guide chemotherapy decisions for metastatic prostate cancer patients. The test helps identify those who will benefit from intensified treatment while sparing others from unnecessary chemotherapy, marking a significant advancement in personalized cancer care.
May 29, 2026 Veracyte Inc. Press Release Highlights Landmark OPTIMA Trial Results The OPTIMA trial showcases how Veracyte's Prosigna test helps high-risk breast cancer patients safely forgo chemotherapy, achieving comparable survival rates. With significant implications for treatment protocols, these findings are set to redefine decision-making in breast cancer care.
May 22, 2026 Veracyte Inc. to Present Groundbreaking Clinical Trial Results at ASCO Annual Meeting Veracyte, Inc. will present pivotal data from the OPTIMA and ENZAMET trials during an investor call on June 1, 2026. Insights from Professor Iain Macpherson will enhance the discussion about their innovative cancer diagnostics. Investors are encouraged to join this critical session.
May 21, 2026 Veracyte Inc. Unveils Promising OPTIMA Trial Results Ahead of ASCO 2026 Veracyte, Inc. announced significant results from its OPTIMA and ENZAMET trials, set to be presented at ASCO 2026. These findings promise to change treatment strategies for breast and prostate cancer, emphasizing personalized care through genomic testing.
May 19, 2026 Veracyte Inc. Set to Showcase Innovations at Upcoming Investor Conferences Veracyte, Inc. will participate in the William Blair and Jefferies conferences in June 2026, focusing on its innovative cancer diagnostics. Live webcasts will be available for investors to engage with the company's latest advancements and strategic vision.
May 06, 2026 Veracyte Inc. Q1 2026 Financial Report: Navigating Growth Amid Challenges Veracyte Inc. reported impressive Q1 2026 results with a revenue of $139 million, a 21% increase from the previous year. Strong testing revenue and strategic investments in R&D reflect the company's commitment to innovation amid macroeconomic challenges.
May 05, 2026 Veracyte Inc. Reports Strong Financial Performance for Q1 2026 Veracyte, Inc. announced strong financial results for Q1 2026, showcasing a 21% revenue increase driven by robust testing volumes. Key products like Decipher and Afirma exceeded expectations, while new launches are set to expand market opportunities.
April 28, 2026 Veracyte Inc. Unveils Promising Data from Decipher Portfolio at AUA 2026 Veracyte, Inc. is set to present over 15 studies on its Decipher portfolio at AUA 2026, focusing on personalized care in bladder and prostate cancers. Key findings aim to refine treatment strategies and improve patient outcomes through advanced molecular subtyping and genomic data analysis.
April 14, 2026 Veracyte Inc. to Announce First Quarter 2026 Financial Results Veracyte, Inc. is set to release its first quarter 2026 financial results on May 5, 2026. A conference call will follow to discuss the results and provide business updates.
March 16, 2026 Veracyte Inc. Appoints Kevin Haas as Chief Development and Technology Officer Veracyte, Inc. has appointed Kevin Haas as its Chief Development and Technology Officer to lead product development in cancer diagnostics. With over 15 years of experience, he aims to innovate with advanced assays and AI technologies, enhancing the company's pipeline and improving patient outcomes.
February 26, 2026 Veracyte Inc. Reports Strong Growth in 2025 Annual Financial Results Veracyte Inc. reported a 16% revenue growth for 2025, totaling $517.1 million, driven by increased testing volume. The company plans to launch new diagnostic tests while facing market challenges such as payer coverage and geopolitical tensions.
February 25, 2026 Veracyte Inc. Reports Strong Financial Results for Q4 and Full Year 2025 Veracyte, Inc. reported a 19% revenue increase in Q4 2025, with significant growth in testing revenue and profitability. CEO Marc Stapley highlighted strong demand for Decipher and Afirma, paving the way for future product launches in 2026.
February 24, 2026 Veracyte Inc. Showcases Breakthrough Data at 2026 ASCO GU Symposium Veracyte, Inc. will present over 15 abstracts at the 2026 ASCO GU Symposium, focusing on its genomic tests, Decipher and TrueMRD, for urologic cancers. Key studies such as the SURE-02 trial will highlight advancements in bladder cancer treatment and the integration of genomic insights into clinical decision-making.
February 19, 2026 Veracyte Inc. Set to Make Waves at Upcoming Investor Conferences Veracyte, Inc. will present at two major investor conferences in March 2026, focusing on its groundbreaking cancer diagnostics. The company aims to engage investors and share its vision for innovative cancer care, providing live webcasts for broader access.
February 04, 2026 Veracyte Inc. Set to Reveal 2025 Financial Results Veracyte, Inc. is set to release its 2025 financial results after market close on February 25, 2026. The announcement will include a conference call for stakeholders to engage with management and gain insights into the company's performance and strategy.
January 11, 2026 Veracyte Inc. Reports Strong Preliminary Financial Results for Q4 and Full-Year 2025 Veracyte Inc. reported impressive preliminary financial results for Q4 and full-year 2025, highlighting a robust increase in revenue and testing volumes. The company anticipates continued growth in 2026, driven by innovative diagnostic solutions and strategic expansions.
December 29, 2025 Veracyte Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference Veracyte, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, showcasing advancements in cancer diagnostics. The company aims to enhance patient care through innovative solutions and will offer live audio webcasts of the presentation.
November 06, 2025 Veracyte Inc. Set to Engage Investors at Upcoming Conferences Veracyte, Inc. will participate in three major investor conferences this November to showcase its innovations in cancer diagnostics. The company aims to engage with investors through presentations and webcasts, detailing its strategic vision and technological advancements.
November 05, 2025 Veracyte Inc. Reports Strong Q3 2025 Results Amidst Macroeconomic Challenges Veracyte Inc. reported impressive Q3 2025 results, with revenues reaching $131.8 million, driven by increased testing revenue. Despite macroeconomic challenges, the company remains focused on innovation and strategic growth.
November 04, 2025 Veracyte Inc. Reports Strong Q3 2025 Financial Results, Boosting Revenue Guidance Veracyte, Inc. reported a 14% rise in total revenue for Q3 2025, driven by a 17% increase in testing revenue. The company raised its full-year revenue guidance and highlighted significant clinical advancements in cancer diagnostics.
November 03, 2025 Veracyte Inc. Unveils Promising Research on Afirma GRID for Thyroid Nodule Testing Veracyte Inc. has published two significant studies on Afirma GRID, a tool designed to improve thyroid nodule evaluation. The research focuses on developing prognostic signatures for better risk assessment before surgery, potentially transforming cancer diagnostics.
October 15, 2025 Veracyte Inc. to Announce Q3 2025 Financial Results Veracyte, Inc. will release its Q3 2025 financial results on November 4, 2025, followed by a conference call offering insights into its operations. The company focuses on advancing cancer diagnostics through innovative technology.
September 28, 2025 Veracyte Inc. Unveils Groundbreaking Biomarker for Prostate Cancer Treatment Veracyte Inc. has unveiled the PAM50 biomarker as a predictive tool for hormone therapy in recurrent prostate cancer, validated by the BALANCE trial. This breakthrough offers a personalized approach to treatment, aiming to enhance patient outcomes and minimize unnecessary side effects.
September 24, 2025 Veracyte Inc. Unveils Groundbreaking Data on Hormone Therapy for Prostate Cancer at ASTRO 2025 Veracyte, Inc. is set to present groundbreaking data on hormone therapy benefits for recurrent prostate cancer at ASTRO 2025. Their innovative Decipher GRID tool analyzes genomic profiles to enhance treatment precision, with significant findings highlighted in nine abstracts at the conference.
August 07, 2025 Veracyte Inc. Reports Q2 2025 Financial Results: A Mixed Bag Amidst Macroeconomic Challenges Veracyte Inc. reported Q2 2025 revenues of $130.1 million, a 13.7% increase, despite rising costs and a non-cash impairment charge. The company faces macroeconomic challenges but aims to enhance growth through strategic acquisitions and new product development.
May 08, 2025 Veracyte Inc. Reports Strong Q1 2025 Results Amidst Macroeconomic Challenges Veracyte Inc. reported impressive Q1 2025 results, showcasing an 18.2% revenue increase to $114.4 million. The company’s robust performance reflects strategic growth initiatives and improved profitability amidst economic challenges.
May 07, 2025 Veracyte Reports Strong Q1 2025 Financial Results Amid Continued Growth in Cancer Diagnostics In Q1 2025, Veracyte reported an 18% revenue increase, driven by robust demand for its Decipher and Afirma cancer diagnostics. The company continues to innovate with new product launches and clinical trials, reinforcing its leadership in the cancer care market.
April 25, 2025 Veracyte Expands Availability of Decipher Prostate Test for Metastatic Cancer Patients Veracyte Inc. has launched the Decipher Prostate Metastatic Genomic Classifier to aid treatment decisions for metastatic prostate cancer patients. This test, covered by Medicare, enhances personalization in treatment and is backed by extensive clinical validation.
April 22, 2025 Veracyte Inc. Unveils Groundbreaking Research at AUA 2025 Veracyte, Inc. will present at AUA 2025 with 18 abstracts focusing on its Decipher Prostate and Bladder Genomic Classifiers, enhancing cancer diagnostics. Key studies will explore immune responses in bladder cancer and molecular features in prostate cancer, aiming to improve personalized patient care.
April 21, 2025 Veracyte Inc. Leverages Real-World Data to Enhance Prostate Cancer Diagnostics Veracyte Inc. has partnered with the NCI SEER Program to integrate its Decipher Prostate Genomic Classifier into a new database, enhancing prostate cancer research. This integration provides vital insights for treatment decisions, aiming to improve patient outcomes through personalized care.
April 16, 2025 Veracyte Inc. Announces First Quarter 2025 Financial Results Release Date Veracyte, Inc. has announced the release date for its Q1 2025 financial results as May 7. A live conference call will follow to discuss business updates and performance insights.
March 25, 2025 Veracyte Inc. Unveils Promising Results for MRD Testing in Bladder Cancer Veracyte Inc. reveals impressive results for its MRD testing platform in bladder cancer, outperforming traditional methods in accuracy and early detection. The TOMBOLA trial highlights the potential for personalized treatment and improved patient outcomes with this innovative technology.
February 28, 2025 Veracyte Inc. Reports Impressive Growth in 2024 Annual Report Veracyte Inc. reported impressive financial growth in its 2024 annual report, with revenues rising to $384.8 million and a return to profitability. The company is focused on enhancing its diagnostic offerings and addressing operational challenges while investing in R&D for future success.
February 24, 2025 Veracyte Inc. Reports Strong Q4 and Full Year 2024 Financial Results Veracyte, Inc. reports record Q4 and full year 2024 results with significant revenue increases driven by strong testing performance. The company anticipates continued growth in its core products, Decipher and Afirma, while emphasizing operational efficiency and strategic advancements.
February 19, 2025 Veracyte Inc. Engages Investors with Upcoming Conference Participation Veracyte, Inc. is set to participate in two significant investor conferences in March, presenting its advancements in cancer diagnostics. The presentations will be available via live webcasts, allowing investors to engage directly with the company's vision and strategy.
February 14, 2025 Veracyte Inc. Unveils Groundbreaking Data at ASCO GU Symposium: A Leap Forward in Cancer Diagnostics Veracyte, Inc. unveiled significant findings at the ASCO GU Symposium, highlighting the efficacy of its Decipher tests in improving treatment strategies for prostate and bladder cancer. Key studies demonstrated how these genomic tools enhance personalized care and optimize radiation therapy outcomes.
February 11, 2025 Veracyte Inc. Showcases Leadership in Urologic Cancer Diagnostics at 2025 ASCO GU Symposium Veracyte Inc. will present 17 abstracts on its Decipher tests at the 2025 ASCO GU Symposium, showcasing advancements in urologic cancer diagnostics. The findings highlight the tests' impact on treatment decisions for patients with prostate and bladder cancers.
February 05, 2025 Veracyte Inc. Unveils Promising Data on Decipher Bladder Test: A Game Changer for Bladder Cancer Staging Veracyte, Inc. has revealed promising data from its Decipher Bladder test, improving bladder cancer staging accuracy and informing treatment decisions. The study highlights significant findings, including 33% of patients experiencing pathological upstaging and the impact of molecular subtypes on survival rates.
January 21, 2025 SWOT Analysis of Veracyte Inc. in 2025 This SWOT analysis examines Veracyte Inc.'s position in cancer diagnostics as of 2025, highlighting its innovative strengths, potential weaknesses, emerging opportunities, and competitive threats. The analysis emphasizes the company's need to leverage its strengths while addressing challenges to maintain growth.
November 07, 2024 Veracyte Inc. Reports Strong Q3 2024 Financial Results, Signaling Growth in Cancer Diagnostics Veracyte, Inc. announced impressive Q3 2024 results with revenue up to $115.8 million and a net profit of $15.15 million, reversing last year's losses. The company continues to expand its diagnostic capabilities and navigate challenges in the healthcare market.
May 08, 2024 Veracyte Inc. Reports Strong Q1 2024 Results: Revenue Growth Despite Increased Expenses Veracyte, Inc. announced a 12% revenue growth in Q1 2024, driven by increased testing demand, although they faced rising operational expenses. The company is focused on managing costs and expanding its testing portfolio for future growth.

Veracyte Reports Strong Q1 2025 Financial Results Amid Continued Growth in Cancer Diagnostics

Last updated: May 07, 2025 •
Taurigo

1. Company Overview

Veracyte, Inc. (Nasdaq: VCYT), a leader in cancer diagnostics, has announced its financial results for the first quarter of 2025, ending March 31. The company, renowned for its innovative diagnostic solutions, reported impressive growth across key metrics, marking its eleventh consecutive quarter of over 20% testing volume growth.

2. CEO Commentary

Marc Stapley, Veracyte's Chief Executive Officer, expressed his optimism regarding the company’s trajectory. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand,” Stapley stated. He emphasized the significance of the recent launch of Decipher for metastatic prostate cancer patients, highlighting the company’s ability to meet evolving patient needs in cancer care. He concluded with a commitment to the company’s vision of transforming cancer care globally.

3. Key Financial Highlights

Veracyte's financial performance for Q1 2025 demonstrated substantial growth compared to the same period in 2024:

  • Total Revenue: Increased by 18% to $114.5 million.
  • Testing Revenue: Rose by 19% to $107.3 million.
  • Total Volume: Grew by 22% to 40,655 tests conducted.
  • Testing Volume: Increased by 23% to 38,078 tests.
  • Decipher Revenue: Saw a remarkable growth of 33% to $66.6 million.
  • Afirma Revenue: Increased by 6% to $38.3 million.
  • Decipher Volume: Expanded by 37% to approximately 22,600 tests.
  • Afirma Volume: Rose by 10% to approximately 15,500 tests.
  • Net Income: Improved to $7.0 million, representing 6.2% of revenue.
  • Adjusted EBITDA: Recorded at $24.7 million, or 21.6% of revenue.
  • Cash from Operations: Generated $5.4 million, ending the quarter with $287.4 million in cash, cash equivalents, and short-term investments.

4. Key Business Highlights

Veracyte's operational achievements in the first quarter also reflect significant advancements in its product offerings and clinical trials:

  • Decipher Launch: The company launched limited access to Decipher for use in the metastatic prostate cancer population, expanding its coverage across the risk spectrum of prostate cancer care.
  • Research Advancements: Veracyte showcased the accuracy of its whole-genome sequencing-based minimal residual disease (MRD) testing platform for muscle-invasive bladder cancer at the EAU25 conference, highlighting new data from the TOMBOLA clinical trial.
  • New Clinical Trials: The company enrolled its first patient into the UMBRELLA trial, which focuses on patients with pancreatic cancer, sarcoma, colorectal cancer, or non-small cell lung cancer (NSCLC), utilizing its differentiated data-driven whole genome MRD approach.
  • Publication of Research: Analytical validity data for the Percepta Nasal Swab was published in *BMC Cancer*, underlining the robustness of its diagnostic offerings.
  • Scientific Presentations: At the AUA 2025 annual meeting, Veracyte presented 18 abstracts centered on its Decipher Prostate, Decipher GRID, and Decipher Bladder Genomic Classifiers, further establishing its thought leadership in the field of urology.

5. Conclusion

Veracyte's financial and operational results from Q1 2025 underscore its continued growth and innovation in cancer diagnostics. With successful product launches and ongoing clinical trials, the company is well-positioned to meet the increasing demand for effective cancer care solutions. As Veracyte moves forward, its commitment to improving patient outcomes remains at the forefront of its strategic initiatives.

Original press release
You may also be interested in:
Products
Resources
Legal
Company
Copyright ©2026 Taurigo GmbH. All rights reserved.Taurigo GmbH provides no investment advice. Any analyses, research, ideas, prices, or other information contained on this website are provided as general market information for educational and entertainment purposes only, and do not constitute investment advice. We assume no responsibility for the accuracy, completeness or timeliness of any financial information contained on this site. In particular, we do not constitute an invitation to buy, sell or hold securities or other financial products. We shall not be liable for any loss or damage, including without limitation loss of profits, arising directly or indirectly from use of or reliance on the provided information. Before making any investment decision, you should consider whether it is suitable for your situation and obtain appropriate financial, tax and legal advice.